Immunovant and Roivant report topline results from IMVT-1402 proof-of-concept study in cutaneous lupus erythematosus

Immunovant announced topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus; parent Roivant Sciences also announced the results. The posts do not state whether the study met its endpoints.

Detected & updated continuously · Source: Nebula